{"id":"https://openalex.org/W2019947260","doi":"https://doi.org/10.1016/s1359-6349(03)90300-4","title":"267 Serum concentrations of MMP-2 and TIMP-1 are of independent prognostic value for cancer specific survival in patients with metastatic colorectal carcinomas under chemotherapy","display_name":"267 Serum concentrations of MMP-2 and TIMP-1 are of independent prognostic value for cancer specific survival in patients with metastatic colorectal carcinomas under chemotherapy","publication_year":2003,"publication_date":"2003-09-01","ids":{"openalex":"https://openalex.org/W2019947260","doi":"https://doi.org/10.1016/s1359-6349(03)90300-4","mag":"2019947260"},"language":"en","primary_location":{"id":"doi:10.1016/s1359-6349(03)90300-4","doi":"https://doi.org/10.1016/s1359-6349(03)90300-4","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s1359-6349(03)90300-4","pdf_url":null,"source":{"id":"https://openalex.org/S13410216","display_name":"European Journal of Cancer Supplements","issn_l":"1359-6349","issn":["1359-6349","1878-1217"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","jufo-1","norway-1","poland-100","russia-white-list-4"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Cancer Supplements","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref","doaj"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5079352063","display_name":"W.M. Bruecki","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"W.M. Bruecki","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064090610","display_name":"A. Wein","orcid":"https://orcid.org/0009-0009-2960-3474","observed_orcids":["https://orcid.org/0009-0009-2960-3474"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. Wein","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003802011","display_name":"Christoph Petry","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. Petry","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001902730","display_name":"Corinna Koebnick","orcid":"https://orcid.org/0000-0001-8274-0309","observed_orcids":["https://orcid.org/0000-0001-8274-0309"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. Koebnick","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071011423","display_name":"Bert Hanke","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"B. Hanke","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005651312","display_name":"V. Bruecki","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"V. Bruecki","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077236374","display_name":"Matthias Hautmann","orcid":"https://orcid.org/0000-0002-1039-0677","observed_orcids":["https://orcid.org/0000-0002-1039-0677"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. Hautmann","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"E.G. Hahn","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"E.G. Hahn","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5101548659","display_name":"Detlef Schuppan","orcid":"https://orcid.org/0000-0002-2716-8239","observed_orcids":["https://orcid.org/0000-0002-2716-8239"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. Schuppan","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":0,"currency":"USD","value_usd":0},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"1","issue":"5","first_page":"S82","last_page":"S82"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.5839999914169312,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.5839999914169312,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10620","display_name":"Protease and Inhibitor Mechanisms","score":0.38350000977516174,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T13437","display_name":"Mechanisms of cancer metastasis","score":0.0032999999821186066,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/mmp-2","display_name":"MMP-2","score":0.9559999704360962},{"id":"https://openalex.org/keywords/timp-1","display_name":"TIMP-1","score":1.0},{"id":"https://openalex.org/keywords/metastatic-colorectal-cancer","display_name":"metastatic colorectal cancer","score":0.9160000085830688},{"id":"https://openalex.org/keywords/cancer-specific-survival","display_name":"cancer-specific survival","score":0.9290000200271606},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.9610000252723694},{"id":"https://openalex.org/keywords/capecitabine","display_name":"capecitabine","score":0.8519999980926514},{"id":"https://openalex.org/keywords/metastatic-breast-cancer","display_name":"metastatic breast cancer","score":0.9580000042915344},{"id":"https://openalex.org/keywords/docetaxel-combination-therapy","display_name":"docetaxel combination therapy","score":0.7400000095367432}],"concepts":[{"id":"https://openalex.org/C2777909004","wikidata":"https://www.wikidata.org/wiki/Q420207","display_name":"Capecitabine","level":4,"score":0.9588142037391663},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8793684840202332},{"id":"https://openalex.org/C2781190966","wikidata":"https://www.wikidata.org/wiki/Q420436","display_name":"Docetaxel","level":3,"score":0.7854876518249512},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.7441271543502808},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.7166609168052673},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.6927332878112793},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.560195803642273},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.5164692401885986},{"id":"https://openalex.org/C2776735402","wikidata":"https://www.wikidata.org/wiki/Q22038268","display_name":"Thymidine phosphorylase","level":3,"score":0.5052514672279358},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.4963722825050354},{"id":"https://openalex.org/C2777982462","wikidata":"https://www.wikidata.org/wiki/Q2481887","display_name":"Adjuvant therapy","level":3,"score":0.4887997806072235},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4728056788444519},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.4449811577796936},{"id":"https://openalex.org/C2776999253","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Combination therapy","level":2,"score":0.4229964017868042},{"id":"https://openalex.org/C2780456651","wikidata":"https://www.wikidata.org/wiki/Q238512","display_name":"Fluorouracil","level":3,"score":0.4198523759841919},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.11097145080566406}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/s1359-6349(03)90300-4","doi":"https://doi.org/10.1016/s1359-6349(03)90300-4","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s1359-6349(03)90300-4","pdf_url":null,"source":{"id":"https://openalex.org/S13410216","display_name":"European Journal of Cancer Supplements","issn_l":"1359-6349","issn":["1359-6349","1878-1217"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","jufo-1","norway-1","poland-100","russia-white-list-4"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Cancer Supplements","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2021179266","https://openalex.org/W2127296490","https://openalex.org/W2735778170","https://openalex.org/W2911150495","https://openalex.org/W2069911708","https://openalex.org/W2004455410","https://openalex.org/W2157900667","https://openalex.org/W2130207808","https://openalex.org/W2101058701","https://openalex.org/W2004666080"],"abstract_inverted_index":null,"counts_by_year":[],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2016-06-24T00:00:00"}